Oncimmune AIMs for £11m target in IPO
This article was originally published in Clinica
Early cancer detection specialist Oncimmune is taking its chance on the public markets and seeking to raise £11m ($15.7m) through an initial public offering on London’s AIM.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.